Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Impact of the major Candida glabrata triazole resistance determinants on the activity of the novel investigational tetrazoles VT-1598 and VT-1161.

Nishimoto AT, Whaley SG, Wiederhold NP, Zhang Q, Yates CM, Hoekstra WJ, Schotzinger RJ, Garvey EP, Rogers PD.

Antimicrob Agents Chemother. 2019 Aug 5. pii: AAC.01304-19. doi: 10.1128/AAC.01304-19. [Epub ahead of print]

PMID:
31383660
2.

Mutations in hmg1, Challenging the Paradigm of Clinical Triazole Resistance in Aspergillus fumigatus.

Rybak JM, Ge W, Wiederhold NP, Parker JE, Kelly SL, Rogers PD, Fortwendel JR.

MBio. 2019 Apr 2;10(2). pii: e00437-19. doi: 10.1128/mBio.00437-19.

3.

In Vitro Activities of the Novel Investigational Tetrazoles VT-1161 and VT-1598 Compared to the Triazole Antifungals against Azole-Resistant Strains and Clinical Isolates of Candida albicans.

Nishimoto AT, Wiederhold NP, Flowers SA, Zhang Q, Kelly SL, Morschhäuser J, Yates CM, Hoekstra WJ, Schotzinger RJ, Garvey EP, Rogers PD.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00341-19. doi: 10.1128/AAC.00341-19. Print 2019 Jun.

PMID:
30910896
4.

A Systematic Screen Reveals a Diverse Collection of Medications That Induce Antifungal Resistance in Candida Species.

Butts A, Reitler P, Nishimoto AT, DeJarnette C, Estredge LR, Peters TL, Veve MP, Rogers PD, Palmer GE.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e00054-19. doi: 10.1128/AAC.00054-19. Print 2019 May.

PMID:
30858206
5.

Contribution of Clinically Derived Mutations in the Gene Encoding the Zinc Cluster Transcription Factor Mrr2 to Fluconazole Antifungal Resistance and CDR1 Expression in Candida albicans.

Nishimoto AT, Zhang Q, Hazlett B, Morschhäuser J, Rogers PD.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e00078-19. doi: 10.1128/AAC.00078-19. Print 2019 May.

PMID:
30833425
6.

The Evolution of Azole Resistance in Candida albicans Sterol 14α-Demethylase (CYP51) through Incremental Amino Acid Substitutions.

Warrilow AG, Nishimoto AT, Parker JE, Price CL, Flowers SA, Kelly DE, Rogers PD, Kelly SL.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02586-18. doi: 10.1128/AAC.02586-18. Print 2019 May.

7.

Abrogation of Triazole Resistance upon Deletion of CDR1 in a Clinical Isolate of Candida auris.

Rybak JM, Doorley LA, Nishimoto AT, Barker KS, Palmer GE, Rogers PD.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e00057-19. doi: 10.1128/AAC.00057-19. Print 2019 Apr.

PMID:
30718246
8.

Emerging threat of triazole-resistant Aspergillus fumigatus.

Rybak JM, Fortwendel JR, Rogers PD.

J Antimicrob Chemother. 2019 Apr 1;74(4):835-842. doi: 10.1093/jac/dky517.

PMID:
30561652
9.

A Hyperactive Form of the Zinc Cluster Transcription Factor Stb5 Causes YOR1 Overexpression and Beauvericin Resistance in Candida albicans.

Ramírez-Zavala B, Manz H, Englert F, Rogers PD, Morschhäuser J.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01655-18. doi: 10.1128/AAC.01655-18. Print 2018 Dec.

10.

Relative Contribution of the ABC Transporters Cdr1, Pdh1, and Snq2 to Azole Resistance in Candida glabrata.

Whaley SG, Zhang Q, Caudle KE, Rogers PD.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01070-18. doi: 10.1128/AAC.01070-18. Print 2018 Oct.

11.

Loss of Upc2p-Inducible ERG3 Transcription Is Sufficient To Confer Niche-Specific Azole Resistance without Compromising Candida albicans Pathogenicity.

Luna-Tapia A, Willems HME, Parker JE, Tournu H, Barker KS, Nishimoto AT, Rogers PD, Kelly SL, Peters BM, Palmer GE.

MBio. 2018 May 22;9(3). pii: e00225-18. doi: 10.1128/mBio.00225-18.

12.

Jjj1 Is a Negative Regulator of Pdr1-Mediated Fluconazole Resistance in Candida glabrata.

Whaley SG, Caudle KE, Simonicova L, Zhang Q, Moye-Rowley WS, Rogers PD.

mSphere. 2018 Feb 21;3(1). pii: e00466-17. doi: 10.1128/mSphere.00466-17. eCollection 2018 Jan-Feb.

13.

Loss of C-5 Sterol Desaturase Activity Results in Increased Resistance to Azole and Echinocandin Antifungals in a Clinical Isolate of Candida parapsilosis.

Rybak JM, Dickens CM, Parker JE, Caudle KE, Manigaba K, Whaley SG, Nishimoto AT, Luna-Tapia A, Roy S, Zhang Q, Barker KS, Palmer GE, Sutter TR, Homayouni R, Wiederhold NP, Kelly SL, Rogers PD.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00651-17. doi: 10.1128/AAC.00651-17. Print 2017 Sep.

14.

Competitive Fitness of Fluconazole-Resistant Clinical Candida albicans Strains.

Popp C, Hampe IAI, Hertlein T, Ohlsen K, Rogers PD, Morschhäuser J.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00584-17. doi: 10.1128/AAC.00584-17. Print 2017 Jul.

15.

An Azole-Tolerant Endosomal Trafficking Mutant of Candida albicans Is Susceptible to Azole Treatment in a Mouse Model of Vaginal Candidiasis.

Peters BM, Luna-Tapia A, Tournu H, Rybak JM, Rogers PD, Palmer GE.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00084-17. doi: 10.1128/AAC.00084-17. Print 2017 Jun.

16.

Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species.

Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD.

Front Microbiol. 2017 Jan 12;7:2173. doi: 10.3389/fmicb.2016.02173. eCollection 2016. Review.

17.

Azole Resistance in Candida glabrata.

Whaley SG, Rogers PD.

Curr Infect Dis Rep. 2016 Dec;18(12):41. Review.

PMID:
27761779
18.

The RTA3 Gene, Encoding a Putative Lipid Translocase, Influences the Susceptibility of Candida albicans to Fluconazole.

Whaley SG, Tsao S, Weber S, Zhang Q, Barker KS, Raymond M, Rogers PD.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6060-6. doi: 10.1128/AAC.00732-16. Print 2016 Oct.

19.

Antifungal adjuvants: Preserving and extending the antifungal arsenal.

Butts A, Palmer GE, Rogers PD.

Virulence. 2017 Feb 17;8(2):198-210. doi: 10.1080/21505594.2016.1216283. Epub 2016 Jul 26. Review.

20.

A Review of Pneumococcal Vaccines: Current Polysaccharide Vaccine Recommendations and Future Protein Antigens.

Daniels CC, Rogers PD, Shelton CM.

J Pediatr Pharmacol Ther. 2016 Jan-Feb;21(1):27-35. doi: 10.5863/1551-6776-21.1.27. Review.

21.

Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.

Rybak JM, Marx KR, Nishimoto AT, Rogers PD.

Pharmacotherapy. 2015 Nov;35(11):1037-51. doi: 10.1002/phar.1652. Epub 2015 Nov 2. Review.

PMID:
26598096
22.

Multidrug Transporters and Alterations in Sterol Biosynthesis Contribute to Azole Antifungal Resistance in Candida parapsilosis.

Berkow EL, Manigaba K, Parker JE, Barker KS, Kelly SL, Rogers PD.

Antimicrob Agents Chemother. 2015 Oct;59(10):5942-50. doi: 10.1128/AAC.01358-15. Epub 2015 Jul 13.

23.

Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans.

Flowers SA, Colón B, Whaley SG, Schuler MA, Rogers PD.

Antimicrob Agents Chemother. 2015 Jan;59(1):450-60. doi: 10.1128/AAC.03470-14. Epub 2014 Nov 10.

24.

Mechanisms of Antifungal Drug Resistance.

Cowen LE, Sanglard D, Howard SJ, Rogers PD, Perlin DS.

Cold Spring Harb Perspect Med. 2014 Nov 10;5(7):a019752. doi: 10.1101/cshperspect.a019752. Review.

25.

Mutational analysis of essential septins reveals a role for septin-mediated signaling in filamentation.

Blankenship JR, Cheng S, Woolford CA, Xu W, Johnson TM, Rogers PD, Fanning S, Nguyen MH, Clancy CJ, Mitchell AP.

Eukaryot Cell. 2014 Nov;13(11):1403-10. doi: 10.1128/EC.00127-14. Epub 2014 Sep 12.

26.

Disruption of the transcriptional regulator Cas5 results in enhanced killing of Candida albicans by Fluconazole.

Vasicek EM, Berkow EL, Bruno VM, Mitchell AP, Wiederhold NP, Barker KS, Rogers PD.

Antimicrob Agents Chemother. 2014 Nov;58(11):6807-18. doi: 10.1128/AAC.00064-14. Epub 2014 Sep 2.

27.

SAGA/ADA complex subunit Ada2 is required for Cap1- but not Mrr1-mediated upregulation of the Candida albicans multidrug efflux pump MDR1.

Ramírez-Zavala B, Mogavero S, Schöller E, Sasse C, Rogers PD, Morschhäuser J.

Antimicrob Agents Chemother. 2014 Sep;58(9):5102-10. doi: 10.1128/AAC.03065-14. Epub 2014 Jun 16.

28.

UPC2A is required for high-level azole antifungal resistance in Candida glabrata.

Whaley SG, Caudle KE, Vermitsky JP, Chadwick SG, Toner G, Barker KS, Gygax SE, Rogers PD.

Antimicrob Agents Chemother. 2014 Aug;58(8):4543-54. doi: 10.1128/AAC.02217-13. Epub 2014 May 27.

29.

UPC2 is universally essential for azole antifungal resistance in Candida albicans.

Vasicek EM, Berkow EL, Flowers SA, Barker KS, Rogers PD.

Eukaryot Cell. 2014 Jul;13(7):933-46. doi: 10.1128/EC.00221-13. Epub 2014 Mar 21.

30.

Mitochondrial two-component signaling systems in Candida albicans.

Mavrianos J, Berkow EL, Desai C, Pandey A, Batish M, Rabadi MJ, Barker KS, Pain D, Rogers PD, Eugenin EA, Chauhan N.

Eukaryot Cell. 2013 Jun;12(6):913-22. doi: 10.1128/EC.00048-13. Epub 2013 Apr 12.

31.

Synchrotron radiation-based far-infrared spectroscopic ellipsometer with full Mueller-matrix capability.

Stanislavchuk TN, Kang TD, Rogers PD, Standard EC, Basistyy R, Kotelyanskii AM, Nita G, Zhou T, Carr GL, Kotelyanskii M, Sirenko AA.

Rev Sci Instrum. 2013 Feb;84(2):023901. doi: 10.1063/1.4789495.

PMID:
23464221
32.

Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans.

Flowers SA, Barker KS, Berkow EL, Toner G, Chadwick SG, Gygax SE, Morschhäuser J, Rogers PD.

Eukaryot Cell. 2012 Oct;11(10):1289-99. doi: 10.1128/EC.00215-12. Epub 2012 Aug 24.

33.

Role of a Candida albicans Nrm1/Whi5 homologue in cell cycle gene expression and DNA replication stress response.

Ofir A, Hofmann K, Weindling E, Gildor T, Barker KS, Rogers PD, Kornitzer D.

Mol Microbiol. 2012 May;84(4):778-94. doi: 10.1111/j.1365-2958.2012.08056.x. Epub 2012 Apr 16.

34.

Echinocandin use in the neonatal intensive care unit.

Caudle KE, Inger AG, Butler DR, Rogers PD.

Ann Pharmacother. 2012 Jan;46(1):108-16. doi: 10.1345/aph.1Q346. Epub 2011 Dec 20. Review.

PMID:
22190252
35.

The transcription factor Ndt80 does not contribute to Mrr1-, Tac1-, and Upc2-mediated fluconazole resistance in Candida albicans.

Sasse C, Schillig R, Dierolf F, Weyler M, Schneider S, Mogavero S, Rogers PD, Morschhäuser J.

PLoS One. 2011;6(9):e25623. doi: 10.1371/journal.pone.0025623. Epub 2011 Sep 27.

36.

Functional dissection of a Candida albicans zinc cluster transcription factor, the multidrug resistance regulator Mrr1.

Schubert S, Popp C, Rogers PD, Morschhäuser J.

Eukaryot Cell. 2011 Aug;10(8):1110-21. doi: 10.1128/EC.05100-11. Epub 2011 Jun 17.

37.

Regulation of efflux pump expression and drug resistance by the transcription factors Mrr1, Upc2, and Cap1 in Candida albicans.

Schubert S, Barker KS, Znaidi S, Schneider S, Dierolf F, Dunkel N, Aïd M, Boucher G, Rogers PD, Raymond M, Morschhäuser J.

Antimicrob Agents Chemother. 2011 May;55(5):2212-23. doi: 10.1128/AAC.01343-10. Epub 2011 Mar 14.

38.

Differential requirement of the transcription factor Mcm1 for activation of the Candida albicans multidrug efflux pump MDR1 by its regulators Mrr1 and Cap1.

Mogavero S, Tavanti A, Senesi S, Rogers PD, Morschhäuser J.

Antimicrob Agents Chemother. 2011 May;55(5):2061-6. doi: 10.1128/AAC.01467-10. Epub 2011 Feb 22.

39.

Genomewide expression profile analysis of the Candida glabrata Pdr1 regulon.

Caudle KE, Barker KS, Wiederhold NP, Xu L, Homayouni R, Rogers PD.

Eukaryot Cell. 2011 Mar;10(3):373-83. doi: 10.1128/EC.00073-10. Epub 2010 Dec 30.

40.

Antimicrobial peptide MUC7 12-mer activates the calcium/calcineurin pathway in Candida albicans.

Lis M, Liu TT, Barker KS, Rogers PD, Bobek LA.

FEMS Yeast Res. 2010 Aug 1;10(5):579-86. doi: 10.1111/j.1567-1364.2010.00638.x. Epub 2010 May 29.

41.

Changes in the proteome of Candida albicans in response to azole, polyene, and echinocandin antifungal agents.

Hoehamer CF, Cummings ED, Hilliard GM, Rogers PD.

Antimicrob Agents Chemother. 2010 May;54(5):1655-64. doi: 10.1128/AAC.00756-09. Epub 2010 Feb 9.

42.

Fluconazole prophylaxis in high-risk neonates.

Reed BN, Caudle KE, Rogers PD.

Ann Pharmacother. 2010 Jan;44(1):178-84. doi: 10.1345/aph.1M364. Epub 2009 Dec 29. Review.

PMID:
20040701
43.

An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicans.

Heilmann CJ, Schneider S, Barker KS, Rogers PD, Morschhäuser J.

Antimicrob Agents Chemother. 2010 Jan;54(1):353-9. doi: 10.1128/AAC.01102-09. Epub 2009 Nov 2.

44.

Computer simulation to aid the risk assessment of wheelchair and special seating systems used in transport.

Rogers PD, Gibson C, Wilcox SJ, Chong A.

J Med Eng Technol. 2009;33(8):642-9. doi: 10.3109/03091900903151004.

PMID:
19848858
45.

The role of voriconazole in the treatment of central nervous system blastomycosis.

Ta M, Flowers SA, Rogers PD.

Ann Pharmacother. 2009 Oct;43(10):1696-700. doi: 10.1345/aph.1M010. Epub 2009 Sep 1. Review.

PMID:
19724015
46.

Proteomic analysis of Mrr1p- and Tac1p-associated differential protein expression in azole-resistant clinical isolates of Candida albicans.

Hoehamer CF, Cummings ED, Hilliard GM, Morschhäuser J, Rogers PD.

Proteomics Clin Appl. 2009 Aug;3(8):968-78. doi: 10.1002/prca.200800252.

47.

The nonmedical use of prescription drugs by adolescents.

Rogers PD, Copley L.

Adolesc Med State Art Rev. 2009 Apr;20(1):1-8, vii. Review.

PMID:
19492687
48.

Identification of the Candida albicans Cap1p regulon.

Znaidi S, Barker KS, Weber S, Alarco AM, Liu TT, Boucher G, Rogers PD, Raymond M.

Eukaryot Cell. 2009 Jun;8(6):806-20. doi: 10.1128/EC.00002-09. Epub 2009 Apr 24.

49.

Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial.

Löwenstein O, Leyendecker P, Hopp M, Schutter U, Rogers PD, Uhl R, Bond S, Kremers W, Nichols T, Krain B, Reimer K.

Expert Opin Pharmacother. 2009 Mar;10(4):531-43. doi: 10.1517/14656560902796798 .

PMID:
19243306
50.

Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains.

Schubert S, Rogers PD, Morschhäuser J.

Antimicrob Agents Chemother. 2008 Dec;52(12):4274-80. doi: 10.1128/AAC.00740-08. Epub 2008 Sep 22.

Supplemental Content

Loading ...
Support Center